Cognitive Behavioral Therapy for Psychosis (CBTp)
Cognitive Behavioral Therapy for Psychosis (CBTp) is a cognitive-behavioral adaptation developed by David Kingdon and Douglas Turkington, whose manual appeared in 1994. Its core mechanism: normalizing psychotic experiences, examining evidence for beliefs and reducing distress associated with symptoms. This catalogue links it to psychosis, typically in individual format, medium-term.
Related condition topics
These links support exploration. They do not establish that CBTp is effective or recommended for each condition.
How Cognitive Behavioral Therapy for Psychosis works
Normalizing psychotic experiences + examining evidence for beliefs + reducing distress associated with symptoms
Ontology
Psychotic symptoms exist on a continuum; distress is driven by appraisal of experiences, not just their presence
Therapeutic Voice
"You mentioned the voices got louder this week. What was happening in your life right before they intensified?"
View of the Person
A person on a continuum of experience whose distress is driven by appraisal of symptoms, not their mere presence
Epistemology
Evidence
1 condition assessment available
An overall effectiveness assessment has not been completed. Completed assessments for specific populations appear below.
Condition-specific assessments
Each conclusion applies to the population and use described. These source-based assessments do not certify the full entry or replace expert clinical review.
Psychosis & Schizophrenia Spectrum
Population and scope: Adults with non-affective psychosis or schizophrenia, as part of coordinated clinical care, including first episodes or recurrent acute episodes.
Guideline recommendation
NICE CG178 offers individual CBT for psychosis, including during acute illness or later (1.4.4.1). First-episode and recurrent acute care combine it with antipsychotic treatment (1.3.4.1; 1.4.2.1). Delivery is manual-based, one to one, with at least 16 planned sessions (1.3.7.1). If medication is declined, 1.3.4.2 specifies monitoring and prompt review. This assessment does not generalize to all affective or substance-induced psychoses.
Source assessment dated
Guidelines and official sources (5)
5 clinical guideline checks
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- Psychosis and schizophrenia in adults: prevention and management (CG178)
Recommendation for the stated population
NICE says to offer CBT to all people within this guideline population.
Scope: Adults with psychosis or schizophrenia, including acute episodes and later care
- Management of First-Episode Psychosis and Schizophrenia
Recommendation for the stated population
VA/DoD suggests CBTp combined with pharmacotherapy (weak for). Preserve the population and combination-treatment scope.
Scope: Adults with prodromal or early psychosis.
- Management of First-Episode Psychosis and Schizophrenia
Recommendation for the stated population
VA/DoD suggests CBTp combined with pharmacotherapy among several psychotherapy options (weak for). It does not establish superiority over every other option.
Scope: Adults with schizophrenia.
- Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders
Recommendation for the stated population
WHO conditionally recommends considering CBT where sufficient specialist support is available, with moderate-certainty evidence. Delivery by non-specialists requires planned specialist supervision.
Scope: Adults with psychotic disorders, including schizophrenia, in the acute phase.
- Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders
Recommendation for the stated population
WHO strongly recommends CBT among the listed psychosocial interventions, with moderate-certainty evidence. The option to use those psychosocial interventions alone or together does not establish that medication should be stopped.
Scope: Adults with psychosis, including schizophrenia, during maintenance treatment.
Recorded material under review
The existing notes below are retained separately from assessment records. These recorded claims await source checking, including study design, recommendations and numerical estimates.
20+ RCTs
Cochrane review (Jones et al., 2018); Jauhar et al. (2014)
NICE-recommended. Effects are modest once outcome-assessment blinding is accounted for: blinded-assessment studies found a non-significant effect on positive symptoms (Jauhar et al., 2014), a live debate in the evidence base.
Training and certification
CBT foundation + psychosis-specific adaptations. Training 2-5 days + supervision
No single body; Beck Institute CBTp track
16-35 hrs + supervised cases
$1K-3K
Equity & Cultural Adaptations
Clinical cautions and blind spots
Assessment and precautions
Acute crisis requiring inpatient stabilization, severe thought disorganization preventing collaborative engagement, active substance intoxication, client refusal or distress from discussing psychotic experiences
Blind spots
Effect sizes debated when controlling for researcher allegiance; may underemphasize social determinants of psychosis
Philosophical roots
Jaspers (form vs. content of psychotic experience); continuum models of psychosis; social constructionism (what counts as delusional is partly social); anti-psychiatry echoes (Laing, Szasz)
Compared with other approaches
Controversies
Ongoing debate about effect sizes when controlling for researcher allegiance and blinding; critics argue CBTp has been ‘oversold’ for psychosis
Jauhar et al. (2014) published a meta-analysis in the British Journal of Psychiatry finding only small effect sizes for CBTp on positive symptoms (d=0.25) and negative symptoms (d=0.13), with effects shrinking further when controlling for blinding bias. The paper triggered a sustained debate about whether CBTp’s benefits for core psychotic symptoms had been overstated in clinical guidelines.
CBTp advocates (Birchwood, Peters, and others) responded that the meta-analysis used overly broad outcome measures (PANSS total scores) rather than targeted symptom measures, and that CBTp primarily targets distress associated with psychotic experiences rather than symptom elimination. Subsequent meta-analyses found stronger effects for specific targets like delusions.
McKenna and Kingdon (2014) argued in BMJ that CBTp had been ‘oversold’ as a treatment for schizophrenia. Laws et al. (2018) extended the critique, finding no significant benefit for quality of life and non-significant effects on functioning at follow-up. The debate highlighted how NICE continued to recommend CBTp despite effect sizes comparable to treatments considered insufficiently supported for other conditions.
CBTp remains recommended by NICE (2014), and defenders argue the debate reflects healthy scientific discourse rather than a fundamental problem. The intervention continues to evolve, with third-wave approaches and targeted interventions for specific symptoms showing stronger effects than generic CBTp protocols.
CBTp in 1 Comparative Clinical Vignette
Each vignette presents the same client through multiple theoretical lenses side by side — showing how CBTp formulates presenting problems, sets treatment focus, and sounds in the consulting room compared with other approaches. This comparative pedagogy is unique to Epoché Clinical; no other clinical reference systematically formulates the same case across traditions.
Test Yourself
CBTp vs. standard CBT?
Show answer
Avoids directly challenging delusions; explores appraisals and reduces distress.